Setmelanotide results: what to expect and when

A daily injection approved for specific genetic obesity and acquired hypothalamic obesity.

Also called: Imcivree, RM-493, BIM-22493, setmelanotide acetate, CAM4072.

Melanocortin agonists · Melanocortin-4 receptor agonist · Evidence: Approved drug.

At least 28 interventional study records, including ongoing studies; rare-obesity trials support approval. Case reports and secondary analyses overlap.

Key studies

  • Energy use: 72-hour infusion: A short infusion raised resting energy use; it did not establish a general weight-loss regimen. (source)
  • MC4R variants: early dose finding: Some MC4R variants responded, but this does not support all MC4R variants or general obesity. (source)
  • First POMC patients: Two adults with POMC deficiency had large reductions in hunger and weight. (source)
  • First LEPR patients: Three LEPR-deficient patients responded during roughly one year of follow-up. (source)
  • POMC/PCSK1: pivotal trial: Weight loss varied by genetic defect; selected responders regained weight during placebo withdrawal. (source)
  • LEPR: pivotal trial: Weight loss varied by genetic defect; selected responders regained weight during placebo withdrawal. (source)

Related to Setmelanotide

Sources

Sources checked: 2026-10-18.

Information only, not medical advice. Peptifacts does not sell anything and does not link to sellers.